

LIST OF TABLES

S.No	Description	Page No.
2.01:	Pharmaceutical Information	96
2.02:	Optimum conditions established in method M_{1a} and M_{1b} for GEMC	129
2.03:	Optimum conditions established in method M₃ for GEMC	130
2.04:	Optimum conditions established in method M₄ for GEMC	131
2.05:	Optimum conditions established in method M₅ for GEMC	132
2.06:	Optimum conditions established in method M₆ and M₇ for GEMC	133
2.07:	Optimum conditions established in method M₈ for GEMC	134
2.08:	Optimum conditions established in method M₉ for GEMC	135
2.09:	Optimum conditions established in method M₁₂ and M₁₃ for GEMC	136
2.10 a:	Optical and regression characteristics, precision and accuracy of the proposed methods for GEMC	137
2.10 b:	Optical and regression characteristics, precision and accuracy of the proposed methods for GEMC	138
2.11a:	Assay of GEMC in Pharmaceutical Formulations	139
2.11b:	Assay of GEMC in Pharmaceutical Formulations	139
2.12:	Chromatographic conditions	144
2.13:	Validation parameters for determination of GEMC by proposed method	150
2.14:	Accuracy/recovery of Gemcitabine	150
2.15:	Intermediate Precision of the method	151
3.01:	Pharmaceutical Information	155
3.02:	Optimum conditions established for methods M_{2a} and M_{2b} for ACFN	174
3.03:	Optimum conditions established in method M₁₀ for ACFN	175

3.04: Optimum conditions established in method M₁₁ for ACFN	175
3.05: Optimum conditions established in method M₁₄ for ACFN	176
3.06: Optimum conditions established in method M₁₅ for ACFN	177
3.07: Optimum conditions established in method M₁₆ for ACFN	178
3.08: Optimum conditions established in method M₁₇ for ACFN	179
3.09: Optimum conditions established in method M₁₈ for ACFN	180
3.10: Optimum conditions established in method M₁₉ for ACFN	181
3.11: Optimum conditions established in method M₂₀ for ACFN	182
3.12 a: Optical and regression characteristics, precision and accuracy of the proposed methods for ACFN	201
3.12 b: Optical and regression characteristics, precision and accuracy of the proposed methods for ACFN	202
3.13a: Assay of ACFN in Pharmaceutical Formulations	203
3.13b: Assay of ACFN in Pharmaceutical Formulations	203
3.14: Chromatographic conditions	205
3.15: Validation parameters for ACFN by proposed method	210
3.16: Results of recovery studies and analysis of formulation	213
4.01: Pharmaceutical Information	218
4.02 : Optical and regression characteristics, precision and accuracy of the proposed methods for DORZ	241
4.03.a: Assay of DORZ in Pharmaceutical Formulations	242
4.03.b: Assay of DORZ in Pharmaceutical Formulations	242
4.04: Chromatographic conditions	248
4.05: Validation parameters for DORZ by proposed method	250
4.06. Results of recovery studies and analysis of formulations	251
5.01: Pharmaceutical Information	257
5.02: Optimum conditions established for method M_{2c} for FEFD	270

5.03 : Optical and regression characteristics, precision and accuracy of the proposed methods for FEFD	271
5.04: Assay of FEFD in Pharmaceutical Formulations	272
5.05: Chromatographic conditions	276
5.06: Optical and Regression Characteristics of the proposed HPLC Method (M₂₄)	281
5.07: Assay and Recovery of fexofenadine	282